What is King Pharmaceuticals's equity method investments?

King Pharmaceuticals (KG) reported equity method investments of $113.8M in Q1 2026.

What does equity method investments mean?

Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.

King Pharmaceuticals KG Equity Method Investments

Equity Method Investments at other companies

Arch Capital GroupACGL

$6.65B+4.9%

Everest GroupEG

$5.96B+9.8%

Skyward Specialty Insurance Group, Inc.SKWD

$72.1M-18.6%

W.R. BerkleyWRB

$1.4B-5.6%

Universal Insurance HoldingsUVE

$10.69M-31.8%

Silvercrest Asset Management GroupSAMG

$2.85M+183%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquityMethodInvestments.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's equity method investments?: King Pharmaceuticals (KG) reported equity method investments of $113.8M in Q1 2026.
What does equity method investments mean?: Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.